[1] SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
[2] XIE Y H, CHEN Y X, FANG J Y. Comprehensive review of targeted therapy for colorectal cancer[J]. Signal Transduct Target Ther, 2020, 5(1): 22.
[3] NARAYANANKUTTY A. PI3K/Akt/mTOR pathway as a therapeutic target for colorectal cancer: a review of preclinical and clinical evidence [J]. Curr Drug Targets, 2019, 20(12): 1217-1226.
[4] YANG Q, JIANG W, HOU P. Emerging role of PI3K/AKT in tumor-related epigenetic regulation[J]. Semin Cancer Biol, 2019, 59: 112-124.
[5] BRADLEY D. Biography of lewis C. cantley[J]. Proc Natl Acad Sci USA, 2004, 101(10): 3327-3328.
[6] FATTAHI S, AMJADI-MOHEB F, TABARIPOUR R, et al. PI3K/AKT/ mTOR signaling in gastric cancer: epigenetics and beyond[J]. Life Sci, 2020, 262: 118513.
[7] SALMENA L, CARRACEDO A, PANDOLFI P P. Tenets of PTEN tumor suppression[J]. Cell, 2008, 133(3): 403-414.
[8] SANAEI M J, BAGHERY SAGHCHY KHORASANI A, POURBAGHERISIGAROODI A, et al. The PI3K/Akt/mTOR axis in colorectal cancer: Oncogenic alterations, non-coding RNAs, therapeutic opportunities, and the emerging role of nanoparticles[J]. J Cell Physiol, 2022, 237(3): 1720-1752.
[9] HUANG H, PARK S, ZHANG H B, et al. Targeting AKT with costunolide suppresses the growth of colorectal cancer cells and induces apoptosis in vitro and in vivo[J]. J Exp Clin Cancer Res, 2021, 40(1): 114.
[10] BACH D H, LONG N P, LUU T T, et al. The dominant role of forkhead box proteins in cancer[J]. Int J Mol Sci, 2018, 19(10): 3279.
[11] DAS V, BHATTACHARYA S, CHIKKAPUTTAIAH C, et al. The basics of epithelial-mesenchymal transition (EMT): a study from a structure, dynamics, and functional perspective[J]. J Cell Physiol, 2019, 234(9): 14535-14555.
[12] CHIN Y R, TOKER A. Function of Akt/PKB signaling to cell motility, invasion and the tumor stroma in cancer[J]. Cell Signal, 2009, 21(4): 470-476.
[13] VERMANI L, KUMAR R, KANNAN R R, et al. Expression pattern of ALDH1, E-cadherin, Vimentin and Twist in early and late onset sporadic colorectal cancer[J]. Biomark Med, 2020, 14(14): 1371-1382.
[14] ABDEL RAOUF S M, IBRAHIM T R, ABDELAZIZ L A, et al. Prognostic value of TWIST1 and EZH2 expression in colon cancer[J]. J Gastrointest Cancer, 2021, 52(1): 90-98.
[15] FOERSTER E G, MUKHERJEE T, CABRAL-FERNANDES L, et al. How autophagy controls the intestinal epithelial barrier[J]. Autophagy, 2022, 18(1): 86-103.
[16] LI J K, SUN H T, JIANG X L, et al. Polyphyllin II induces protective autophagy and apoptosis via inhibiting PI3K/AKT/mTOR and STAT3 signaling in colorectal cancer cells[J]. Int J Mol Sci, 2022, 23(19): 11890.
[17] ESTÈVE P O, CHANG Y Q, SAMARANAYAKE M, et al. A methylation and phosphorylation switch between an adjacent lysine and serine determines human DNMT1 stability[J]. Nat Struct Mol Biol, 2011, 18(1): 42-48.
[18] LIN P C, LIN J K, LIN H H, et al. A comprehensive analysis of phosphatase and tensin homolog deleted on chromosome 10(PTEN) loss in colorectal cancer[J]. World J Surg Oncol, 2015, 13: 186.
[19] WANG C, CHEN J X, KUANG Y Y, et al. A novel methylated cation channel TRPM4 inhibited colorectal cancer metastasis through Ca2+/ Calpain-mediated proteolysis of FAK and suppression of PI3K/Akt/ mTOR signaling pathway[J]. Int J Biol Sci, 2022, 18(14): 5575-5590.
[20] HUO M M, ZHANG J Y, HUANG W, et al. Interplay among metabolism, epigenetic modifications, and gene expression in cancer[J]. Front Cell Dev Biol, 2021, 9: 793428.
[21] FENG J T, CEN J H, LI J, et al. Histone deacetylase inhibitor valproic acid (VPA) promotes the epithelial mesenchymal transition of colorectal cancer cells via up regulation of Snail[J]. Cell Adh Migr, 2015, 9(6): 495-501.
[22] CHEN X X, XU M, XU X N, et al. METTL14-mediated N6-methyladenosine modification of SOX4 mRNA inhibits tumor metastasis in colorectal cancer[J]. Mol Cancer, 2020, 19(1): 106.
[23] SANCHES J G P, SONG B, ZHANG Q Q, et al. The role of KDM2B and EZH2 in regulating the stemness in colorectal cancer through the PI3K/ AKT pathway[J]. Front Oncol, 2021, 11: 637298.
[24] XU L J, ZHANG Y, WANG H, et al. Tumor suppressor miR-1 restrains epithelial-mesenchymal transition and metastasis of colorectal carcinoma via the MAPK and PI3K/AKT pathway[J]. J Transl Med, 2014, 12: 244.
[25] DU G H, YU X L, CHEN Y, et al. miR-1-3p suppresses colorectal cancer cell proliferation and metastasis by inhibiting YWHAZmediated epithelial-mesenchymal transition[J]. Front Oncol, 2021, 11: 634596.
[26] QIN A C, QIAN W F. microRNA-7 inhibits colorectal cancer cell proliferation, migration and invasion via TYRO3 and phosphoinositide 3-kinase/protein B kinase/mammalian target of rapamycin pathway suppression[J]. Int J Mol Med, 2018, 42(5): 2503-2514.
[27] MOAFIAN Z, MAGHROUNI A, SOLTANI A, et al. Cross-talk between non-coding RNAs and PI3K/AKT/mTOR pathway in colorectal cancer [J]. Mol Biol Rep, 2021, 48(5): 4797-4811.
[28] GHAZANCHAEI A, MANSOORI B, MOHAMMADI A, et al. Restoration of miR-152 expression suppresses cell proliferation, survival, and migration through inhibition of AKT-ERK pathway in colorectal cancer[J]. J Cell Physiol, 2018, 234(1): 769-776.
[29] CHEN Y Y, JIANG J W, ZHAO M Y, et al. microRNA-374a suppresses colon cancer progression by directly reducing CCND1 to inactivate the PI3K/AKT pathway[J]. Oncotarget, 2016, 7(27): 41306-41319.
[30] XIONG B H, CHENG Y, MA L, et al. miR-21 regulates biological behavior through the PTEN/PI-3 K/Akt signaling pathway in human colorectal cancer cells[J]. Int J Oncol, 2013, 42(1): 219-228.
[31] LIU H W, WANG J, TAO Y X, et al. Curcumol inhibits colorectal cancer proliferation by targeting miR-21 and modulated PTEN/PI3K/ Akt pathways[J]. Life Sci, 2019, 221: 354-361.
[32] LAI C Y, YEH K Y, LIU B F, et al. microRNA-21 plays multiple oncometabolic roles in colitis-associated carcinoma and colorectal cancer via the PI3K/AKT, STAT3, and PDCD4/TNF-α signaling pathways in zebrafish[J]. Cancers (Basel), 2021, 13(21): 5565.
[33] NI H L, HAN Y J, JIN X H. Celastrol inhibits colon cancer cell proliferation by downregulating miR-21 and PI3K/AKT/GSK-3β pathway[J]. Int J Clin Exp Pathol, 2019, 12(3): 808-816.
[34] CORONEL-HERNÁNDEZ J, LÓPEZ-URRUTIA E, CONTRERASROMERO C, et al. Cell migration and proliferation are regulated by miR-26a in colorectal cancer via the PTEN-AKT axis[J]. Cancer Cell Int, 2019, 19: 80.
[35] KE T W, WEI P L, YEH K T, et al. miR-92a promotes cell metastasis of colorectal cancer through PTEN-mediated PI3K/AKT pathway[J]. Ann Surg Oncol, 2015, 22(8): 2649-2655.
[36] QIN Y, HUO Z B, SONG X, et al. miR-106a regulates cell proliferation and apoptosis of colon cancer cells through targeting the PTEN/PI3K/AKT signaling pathway[J]. Oncol Lett, 2018, 15(3): 3197-3201.
[37] ZHENG L, ZHANG Y Q, LIU Y, et al. miR-106b induces cell radioresistance via the PTEN/PI3K/AKT pathways and p21 in colorectal cancer[J]. J Transl Med, 2015, 13: 252.
[38] YANG C G, DOU R Z, WEI C, et al. Tumor-derived exosomal microRNA-106b-5p activates EMT-cancer cell and M2-subtype TAM interaction to facilitate CRC metastasis[J]. Mol Ther, 2021, 29(6): 2088-2107.
[39] XUE Y, MA G X, GU D Y, et al. Genome-wide analysis of long noncoding RNA signature in human colorectal cancer[J]. Gene, 2015, 556(2): 227-234.
[40] SHAO Q W, XU J, DENG R, et al. Long non-coding RNA-422 acts as a tumor suppressor in colorectal cancer[J]. Biochem Biophys Res Commun, 2018, 495(1): 539-545.
[41] MENG S, JIAN Z, YAN X F, et al. LncRNA SNHG6 inhibits cell proliferation and metastasis by targeting ETS1 via the PI3K/AKT/mTOR pathway in colorectal cancer[J]. Mol Med Rep, 2019, 20(3): 2541-2548.
[42] SHANG A Q, WANG W W, YANG Y B, et al. Knockdown of long noncoding RNA PVT1 suppresses cell proliferation and invasion of colorectal cancer via upregulation of microRNA-214-3p[J]. Am J Physiol Gastrointest Liver Physiol, 2019, 317(2): G222-G232.
[43] LIU B, PAN S M, XIAO Y, et al. LINC01296/miR-26a/GALNT3 axis contributes to colorectal cancer progression by regulating O-glycosylated MUC1 via PI3K/AKT pathway[J]. J Exp Clin Cancer Res, 2018, 37(1): 316.
[44] ZHANG Y, LIU X X, ZHANG J Y, et al. Inhibition of miR-19a partially reversed the resistance of colorectal cancer to oxaliplatin via PTEN/PI3K/AKT pathway[J]. Aging (Albany NY), 2020, 12(7): 5640-5650.
[45] DENG X, KONG F Y, LI S, et al. A KLF4/PiHL/EZH2/HMGA2 regulatory axis and its function in promoting oxaliplatin-resistance of colorectal cancer[J]. Cell Death Dis, 2021, 12(5): 485.
[46] SUN L N, FANG Y, WANG X, et al. miR-302a inhibits metastasis and cetuximab resistance in colorectal cancer by targeting NFIB and CD44[J]. Theranostics, 2019, 9(26): 8409-8425.
[47] HUANG K C, CHIANG S F, CHEN W T, et al. Decitabine augments chemotherapy-induced PD-L1 upregulation for PD-L1 blockade in colorectal cancer[J]. Cancers (Basel), 2020, 12(2): 462. |
